BDNF and the exercising brain — the neurotrophin that links movement to memory

BDNF belongs to the neurotrophins, a family of proteins whose job is to nurture neurons. But survival is only the beginning of what it does. BDNF promotes the growth of dendrites and axons, the branching extensions through which neurons reach and connect to one another. It strengthens synapses — the junctions where one neuron passes a signal to the next — and it is required for long-term potentiation, the durable strengthening of synaptic connections that neuroscientists regard as the cellular foundation of learning and memory. It supports adult neurogenesis, the birth of new neurons in the hippocampus, the brain's memory-forming structure, which is one of the few regions where new neurons are generated throughout adult life. In short, BDNF is not merely a maintenance protein. It is a growth and plasticity signal, the chemical that tells the brain it is allowed to change.

Most of these effects run through a single receptor. BDNF binds with high affinity to TrkB, a receptor tyrosine kinase studded across neuronal membranes. When BDNF docks onto TrkB, the receptor pairs up and switches on a cascade of intracellular signaling — the same broad families of pathways, including the PI3K-Akt, MAPK, and PLCγ routes, that cells use to make decisions about survival, growth, and gene expression. Downstream, these signals converge on transcription factors that turn on the genes for synaptic proteins and further BDNF production, creating a self-reinforcing loop. There is a complication worth noting: BDNF is first made as a precursor called proBDNF, and proBDNF can bind a different receptor, p75, which tends to push neurons toward pruning and apoptosis rather than growth. The balance between mature BDNF and its precursor is part of how the same molecule can support either the strengthening or the elimination of connections, depending on context. This is the first hint that "more BDNF" is not a simple lever.

The discovery that reshaped popular interest in BDNF was its tight coupling to physical exercise. In the 1990s, Carl Cotman and colleagues showed that rodents given access to a running wheel had substantially elevated BDNF in the hippocampus, and that the increase tracked with how much the animals ran. The relationship turned out to be robust and repeatable, and it has since been documented in humans. Aerobic exercise — sustained, rhythmic, cardiovascular activity that raises the heart rate, the kind of effort involved in running, cycling, swimming, or brisk hiking — produces an acute rise in circulating BDNF, with the magnitude of the rise scaling with the intensity and duration of the effort. The mechanism is layered. Contracting skeletal muscle releases signaling molecules into the blood, among them irisin, a hormone cleaved from the membrane protein FNDC5, and irisin signaling has been shown to drive BDNF expression in the hippocampus. Exercise also raises circulating lactate, which the brain takes up and which itself promotes BDNF production, and during fasting or intense exertion the liver produces ketone bodies such as beta-hydroxybutyrate, which has been shown to increase BDNF gene expression through effects on chromatin. Layered on top of all this is the simple fact that exercise increases neuronal activity, and active neurons make more BDNF. Movement, in other words, talks to the brain through several channels at once, and BDNF is where many of those channels converge.

This is why the case for exercise as cognitive support is mechanistically stronger than for almost any supplement. Aerobic training is associated, in human studies, with larger hippocampal volume, better performance on memory tasks, and slower age-related cognitive decline, and BDNF is the most credible molecular mediator linking the activity to the outcome. The effects of resistance training on BDNF are real but more modest and less consistent in the literature than those of aerobic work, which suggests that the cardiovascular component — the sustained elevation of heart rate and the metabolic signals it generates — is doing much of the work. The practical implication is unusually clean for neuroscience: the single most reliable way a person can raise BDNF is to do cardiovascular exercise regularly.

The mood connection is the other half of BDNF's importance, and it emerged from depression research. A central modern theory of depression, the neurotrophic hypothesis, holds that chronic stress and depression are associated with reduced BDNF and impaired neuroplasticity, particularly in the hippocampus and prefrontal cortex, and that effective antidepressant treatments work in part by restoring BDNF signaling. The evidence is substantial: chronic stress lowers BDNF in animal models, people with major depression tend to have lower circulating BDNF that rises with successful treatment, and conventional antidepressants increase BDNF expression over the weeks that correspond to their clinical onset. The most striking entry in this story is ketamine, whose rapid antidepressant effect has been linked to a fast burst of BDNF release and TrkB activation that drives quick synaptic remodeling — a finding that helped move the field toward viewing depression as, in part, a disorder of plasticity rather than simply a chemical imbalance of one neurotransmitter. None of this means low BDNF is the singular cause of depression; it means BDNF sits close to the mechanisms that depression disrupts and that treatment restores.

Genetics adds an important wrinkle. A common variant of the BDNF gene, known as Val66Met, changes a single amino acid in the proBDNF region and reduces the efficiency with which BDNF is packaged and released in response to neuronal activity. People who carry the Met variant — a substantial fraction of the population — show, on average, subtle differences in memory performance, hippocampal structure, and stress reactivity, and the variant has been studied as a modifier of risk and treatment response in several psychiatric and neurological conditions. The effect of any one gene is small, but Val66Met is a useful reminder that BDNF biology is not identical across people, and that the same intervention may shift the system differently depending on the underlying genetics.

In the neurodegenerative diseases, BDNF appears as a thread running through the pathology. In Alzheimer's disease, BDNF levels are reduced in the hippocampus and cortex, and the reduction correlates with the severity of cognitive impairment; because BDNF supports the very synapses that Alzheimer's destroys, its decline is both a marker of the disease and a plausible contributor to it, and restoring BDNF signaling has been an active target of preclinical research. In Parkinson's disease, BDNF supports the survival of dopaminergic neurons in the substantia nigra — the cells whose loss produces the motor symptoms — and reduced BDNF has been documented in Parkinson's brains. In Huntington's disease, the mutant huntingtin protein interferes with the normal transport and production of BDNF, depriving the striatal neurons that degenerate in the disease of a survival signal they depend on. Across these conditions BDNF is not the cause, but it is repeatedly implicated as part of the machinery of neuronal resilience that fails. This has made the neurotrophin an attractive therapeutic idea for decades — and also a frustrating one, because BDNF itself is a large protein that does not cross the blood-brain barrier well and is cleared quickly, which is why simply injecting it has not translated into therapy, and why much of the research effort has shifted toward finding ways to raise the brain's own BDNF or to activate the TrkB receptor downstream.

This is the context in which the research peptides enter the conversation, and it calls for precision about the evidence. Semax is a synthetic peptide derived from a fragment of adrenocorticotropic hormone (ACTH), developed in Russia, where it has been used clinically for stroke and cognitive indications; it is not approved by the FDA and is considered a research compound in the United States. Among the mechanisms reported in the preclinical literature, Semax has been shown in animal and cell studies to increase expression of BDNF and its receptor in the hippocampus, alongside effects on other neurotrophic and neuromodulatory systems. Selank, similarly developed in Russia, is a synthetic analog of the immunomodulatory peptide tuftsin, studied primarily for anxiolytic effects, and some preclinical work likewise reports changes in BDNF expression among its actions. Cortexin is a polypeptide preparation derived from animal cerebral cortex, used in Russian neurology and studied in that clinical tradition, with claimed neurotrophic and neuroprotective effects. The honest summary is that these compounds have coherent, interesting mechanisms that intersect BDNF signaling, that much of the supporting evidence is preclinical or comes from clinical settings outside the framework of large Western randomized trials, and that none is an FDA-approved therapy. They are studied for these pathways; they have not been shown, in rigorous human trials, to treat the cognitive or mood conditions in which BDNF is implicated. Any consideration of them belongs with your prescribing provider, who can weigh the regulatory status and the thinness of the human evidence.

What does the broader evidence actually support for raising BDNF? Exercise, first and most reliably. Beyond that, several lifestyle factors are associated with higher BDNF in the research: intermittent fasting and caloric restriction, which raise BDNF partly through the ketone-body mechanism noted earlier; quality sleep, particularly deep slow-wave sleep, during which the brain consolidates the plasticity that BDNF supports, with sleep deprivation lowering it; sunlight and adequate vitamin D status; omega-3 fatty acids, especially DHA, which support BDNF expression in animal models; and the reduction of chronic stress and inflammation, both of which suppress BDNF. Certain dietary compounds — curcumin, the polyphenols in green tea, and others — have shown BDNF-supportive effects in preclinical work, though human data are thinner. None of these is dramatic in isolation. Their value is cumulative and convergent: the same habits that protect the brain through every other mechanism also tend to support BDNF.

The limit of the "raise your BDNF" framing is worth stating plainly, because it has become a marketing shorthand that the biology does not really endorse. Circulating BDNF, the kind measured in a blood test, correlates only loosely with BDNF in the brain, where it actually does its work, and a single blood number is a noisy and indirect proxy. More is not always better — recall that the precursor proBDNF acts through a different receptor with opposite effects, and that BDNF's job is sometimes to prune connections rather than build them. BDNF is one node in a dense network of neurotrophins, neurotransmitters, and signaling systems, and the brain's plasticity emerges from the whole network, not from any single molecule's concentration. Treating BDNF as a dial you turn up is the same category error as treating telomere length as a master clock: it takes a real and important biomarker and inflates it into a control knob it was never designed to be.

What the research genuinely supports is humbler and more useful than the slogan. BDNF is the molecule through which physical movement reaches the parts of the brain responsible for memory and mood, which is why a body in motion tends to house a more resilient mind. That link is among the best-established findings in all of neuroscience, and it does not require a supplement to access. The neurotrophin Barde first coaxed out of pig brain in 1982 turned out to be the chemical answer to an old intuition — that walking clears the head, that a hard run lifts the spirits, that the active body and the sharp mind tend to keep company. The mechanism is real, and the most dependable way to engage it is also the oldest.